Ten-day Decitabine with Venetoclax vs. Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis

Ten-day decitabine with venetoclax (DEC10-VEN) offers potentially better outcomes compared to intensive chemotherapy for patients with relapsed or refractory acute myeloid leukemia. DEC10-VEN was associated with higher response rates, MRD-negativity and longer overall and event-free survival compare...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2021-08, Vol.127 (22), p.4213-4220
Main Authors: Maiti, Abhishek, DiNardo, Courtney D., Qiao, Wei, Kadia, Tapan M., Jabbour, Elias J., Rausch, Caitlin R., Daver, Naval G., Short, Nicholas J., Borthakur, Gautam, Pemmaraju, Naveen, Yilmaz, Musa, Alvarado, Yesid, Montalbano, Kathryn S., Wade, Allison, Maduike, Rita E., Guerrero, Julio A., Vaughan, Kenneth, Bivins, Carol A., Pierce, Sherry, Ning, Jing, Ravandi, Farhad, Kantarjian, Hagop M., Konopleva, Marina Y.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ten-day decitabine with venetoclax (DEC10-VEN) offers potentially better outcomes compared to intensive chemotherapy for patients with relapsed or refractory acute myeloid leukemia. DEC10-VEN was associated with higher response rates, MRD-negativity and longer overall and event-free survival compared to intensive chemotherapy in R/R AML.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.33814